The early detection of renal cell carcinoma (RCC) using serum/plasma biomarkers remains challenging. According to data published in Cancer Epidemiology, Biomarkers & Prevention, a journal of the American Association for Cancer Research, a new immunoassay that tests for the presence of three biomarkers may be a valid screening method for the early detection of malignant kidney cancer.
?Renal cell carcinoma, a malignant tumor arising from the kidney, is one of the most difficult forms of cancer to detect and treat properly because it remains silent until disseminating to other organs,? explaind Nam Hoon Cho, M.D., of the Department of Pathology at Yonsei University Health System in Seoul, Korea. ?Furthermore, because imaging, which is high-cost, is seldom performed without any specific reasons, developing a blood-tumor biomarker is a great chance to detect the silent killer.?[1]
In the United States, Renal cell carcinoma (RCC) is the eighth most common malignancy affecting adults. The disease accounts for 3% and 4% of all new cancers. It is the seventh most common cancer in men and the ninth most common in women and represents a family of related disorders with distinct cytogenetic and immunohistochemical properties that have differing prognoses, imaging characteristics, and potential morbidities.[2]
Potential biomarkers
The new immunoassay developed by Cho and colleagues from Genomine Inc., a company focused on the discovery, development and commercialization of biomarkers and diagnostic kits for early detection of cancers, measured the levels of three potential biomarkers for kidney cancer: nicotinamide N-methyltransferase (NNMT), L-plastin (LCP1) and nonmetastatic cells 1 protein (NM23A).
Using this assay, the researchers measured concentrations of NNMT, LCP1 and NM23A in 189 plasma samples from 102 healthy controls and patients with benign tumors and 87 patients with kidney cancer. Plasma levels indicated that all three biomarkers were highly elevated in patients with kidney cancer. For example, the median level of NNMT concentration in healthy controls was 68 pg/mL compared with 420 pg/mL for patients with kidney cancer.
Next, the researchers tested the ability of the immunoassay to distinguish plasma samples from healthy controls and patients with kidney cancer using the same 189 plasma samples already tested. The results indicated that the three-marker assay was highly accurate. When it correctly identified 90% of the samples from healthy controls, it also correctly identified 94.4% of the samples from patients with kidney cancer.
Validation
To validate the accuracy of the test, the researchers blind tested an additional 100 plasma samples from 73 healthy controls and 27 patients with kidney cancer. In this analysis, 67 of the samples from the 73 healthy controls and all of the samples from patients with kidney cancer were classified correctly.
?If this biomarker is truly valid and accurate to detect renal cell carcinoma, a number of patients with renal cell carcinoma could potentially be saved through early diagnosis,? Cho noted.
The researchers hope that this biomarker will soon be commercially available. They are currently working toward approval by the U.S. Food and Drug Administration (FDA).
For more information:
[1] Kim DS, Choi YD, Moon M, Kang S, Lim JB, Kim KM, Park KM, Cho NH Composite Three-Marker Assay for Early Detection of Kidney Cancer.
Cancer Epidemiol Biomarkers Prev March 2013 22; 390 doi: 10.1158/1055-9965.EPI-12-1156
[2] Ng CS, Wood CG, Silverman PM, Tannir NM, Tamboli P, Sandler CM. Renal Cell Carcinoma: Diagnosis, Staging, and Surveillance AJR Am J Roentgenol. 2008 Oct;191(4):1220-32. doi: 10.2214/AJR.07.3568.[Abstract] [Full Article]
Copyright ? 2013 InPress Media Group/Sunvalley Communication. All rights reserved. Republication or redistribution of InPress Media Group/Sunvalley Communication content, including by framing or similar means, is expressly prohibited without the prior written consent of InPress Media Group/Sunvalley Communication. InPress Media Group/Sunvalley Communication shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. Onco’Zine and Oncozine are registered trademarks and trademarks of Sunvalley Communication around the world.
